Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortalities
worldwide. Patients with early-stage HCC are eligible for curative treatments, such as …

Simple Summary The prognostic evaluation and therapeutic management of
hepatocarcinoma (HCC) is based on the Barcelona Liver Cancer Clinic (BCLC). In the past …

Hepatocellular carcinoma (HCC), with rising incidence rates, is the most commonly
occurring malignancy of the liver that exerts a heavy disease burden particularly in …

Liver cancer is one of the most common malignancies, and various pathogenic factors can
lead to its occurrence and development. Among all primary liver cancers, hepatocellular …

Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis
of patients with advanced stage of disease remains unfavorable. Several immune therapies …

The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with
limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA …

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a poor
prognosis due to advanced disease presentation or recurrence despite curative‐intent …

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is derived mostly
from a background of chronic inflammation. Multiple immunotherapeutic strategies have …